Table 2. Results of various studies showing the role of Hs-CRP in CVD.

Hs-CRP: High-sensitivity C-reactive protein, CVD: Cardiovascular diseases.

Sr. No	Author/ Year [Reference]	Type of Study	Conclusion
1	Kandelouei et al (2022) [41]	Systematic review and meta-analysis	This systematic review and meta-analysis showed that the statins are efficacious in reducing the concentrations of CRP and Hs-CRP in patients with different types of cardiovascular diseases and coronary artery diseases like acute coronary syndrome, myocardial infarction, stable atherosclerotic plaques, and unstable angina.
2	Gholoobi et al (2021) [42]	Randomized, placebo-controlled, double-blind clinical trial.	Hs-CRP is an important inflammatory marker for non-ST-segment elevation myocardial infarction and is related to cardiovascular events.
3	Carrero et al (2019) [34]	Randomized controlled trial	Most patients with myocardial infarction exhibit elevated Hs-CRP levels and Hs-CRP ≥2 mg/L levels were associated with a higher risk of major adverse cardiovascular events (adjusted hazard ratio, 1.28) and death (adjusted hazard ratio, 1.42). Increased Hs-CRP levels have prognostic validity as biomarkers beyond the trial evidence; in real‐world healthcare-based settings.
4	Tayefi et al (2017) [43]	Decision tree algorithm	This study indicated that serum Hs-CRP levels are the most important variable associated with coronary artery diseases and this biomarker has a stronger association with coronary heart disease in comparison to traditional biomarkers such as fasting blood glucose and low-density lipoproteins.
5	Li et al (2017) [44]	Meta-analysis	The risk of cardiovascular mortality increased by 2.03 times among study subjects with the highest Hs-CRP levels. Hs-CRP can stratify all-cause and cardiovascular mortality risks in the general population.
6	Wang et al (2017) [45]	Cross-sectional	This study concluded that cumulative exposure to Hs‐CRP was associated with a subsequent increased risk of CVD and myocardial infarction in a dose-dependent manner. Cumulative measurements of Hs-CRP are better than single measurement of risk prediction of disease development of CVD and myocardial infarction.